Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Average Recommendation of “Hold” from Brokerages

Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Free Report) has earned an average rating of “Hold” from the ten analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $35.00.

Several research firms have commented on IART. Bank of America dropped their target price on shares of Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a research report on Tuesday, May 7th. Citigroup lifted their price target on shares of Integra LifeSciences from $24.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday. Morgan Stanley lowered their price target on shares of Integra LifeSciences from $37.00 to $24.00 and set an “underweight” rating on the stock in a report on Tuesday, May 7th. Truist Financial lowered their price target on shares of Integra LifeSciences from $37.00 to $25.00 and set a “hold” rating on the stock in a report on Tuesday, May 7th. Finally, StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Monday, May 13th.

Get Our Latest Report on IART

Insider Transactions at Integra LifeSciences

In other news, Chairman Stuart Essig bought 52,641 shares of the company’s stock in a transaction dated Thursday, May 23rd. The stock was bought at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the completion of the acquisition, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.10% of the stock is currently owned by company insiders.

Institutional Trading of Integra LifeSciences

A number of institutional investors have recently modified their holdings of IART. Vanguard Group Inc. lifted its holdings in Integra LifeSciences by 1.0% in the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after buying an additional 72,294 shares during the period. Capital Research Global Investors lifted its holdings in Integra LifeSciences by 37.7% in the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after buying an additional 1,621,655 shares during the period. Cooke & Bieler LP lifted its holdings in Integra LifeSciences by 4.4% in the fourth quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock worth $123,447,000 after buying an additional 120,410 shares during the period. Champlain Investment Partners LLC lifted its holdings in Integra LifeSciences by 10.3% in the first quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock worth $95,289,000 after buying an additional 252,015 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Integra LifeSciences by 4.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock worth $70,340,000 after buying an additional 63,323 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $28.31 on Tuesday. The company has a current ratio of 4.68, a quick ratio of 3.35 and a debt-to-equity ratio of 1.15. The business has a 50-day moving average price of $30.53 and a two-hundred day moving average price of $37.34. The company has a market cap of $2.23 billion, a P/E ratio of 56.62, a PEG ratio of 1.03 and a beta of 1.17. Integra LifeSciences has a 1-year low of $22.36 and a 1-year high of $46.75.

Integra LifeSciences (NASDAQ:IARTGet Free Report) last issued its earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, meeting the consensus estimate of $0.55. The company had revenue of $368.90 million during the quarter, compared to the consensus estimate of $361.96 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period last year, the business posted $0.74 EPS. As a group, analysts anticipate that Integra LifeSciences will post 3.03 EPS for the current year.

Integra LifeSciences Company Profile

(Get Free Report

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

See Also

Analyst Recommendations for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.